ClinConnect ClinConnect Logo
Search / Trial NCT07040163

Evaluation of Ketamine/Midazolam Deep Sedation vs. Fentanyl/Midazolam Moderate Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology

Launched by CAMC HEALTH SYSTEM · Jun 24, 2025

Trial Information

Current as of July 06, 2025

Recruiting

Keywords

Ketamine Interventional Radiology Fentanyl Sedation

ClinConnect Summary

This clinical trial is studying two different ways to help patients feel comfortable and less painful during certain medical procedures where doctors use imaging to guide small biopsies (taking a tiny sample of tissue) or drain fluid from the body. Usually, patients receive medicines called fentanyl and midazolam to help them relax and reduce pain. This study is comparing that standard approach with a different combination of medicines, ketamine and midazolam, to see if ketamine might reduce pain better and improve how satisfied patients feel during the procedure, without causing more side effects.

Adults aged 18 to 89 who are scheduled for image-guided bone or lung biopsies, or drainage procedures, and who can safely receive either type of sedation may be able to join. People who are pregnant, currently taking certain opioid medications, or have specific health issues like uncontrolled high blood pressure or schizophrenia cannot take part. Participants will be randomly assigned to receive one of the two sedation methods, and the study team will check how much pain they feel, how happy they are with the experience, if they need any extra medicine, and watch for any side effects. The goal is to find a better way to make these procedures as comfortable and safe as possible.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Planned to undergo image-guided bone biopsy, lung biopsy, or percutaneous drainage
  • Eligible to receive ketamine or fentanyl sedation
  • Any sex/gender, any race
  • Aged 18-89
  • Exclusion Criteria:
  • Pregnant/lactating
  • Incarceration
  • Currently taking an opioid agonist/antagonist
  • Food consumed in past 6-8 hours
  • Allergies to drugs used in the study
  • Lacks mental capacity for reporting pain scores
  • Hypotension or respiratory failure precluding fentanyl sedation
  • Uncontrolled hypertension precluding ketamine sedation
  • Condition for which hypertension would be a concern
  • Schizophrenia

About Camc Health System

CAMC Health System is a comprehensive healthcare organization based in Charleston, West Virginia, dedicated to enhancing patient care through innovative clinical research and trials. As a leading sponsor of clinical studies, CAMC Health System focuses on advancing medical knowledge and treatment options across various specialties, including cardiology, oncology, and neurology. With a commitment to ethical standards, patient safety, and community health, CAMC collaborates with researchers and healthcare professionals to facilitate groundbreaking studies that aim to improve health outcomes and quality of life for patients both locally and beyond.

Locations

Charleston, West Virginia, United States

Patients applied

0 patients applied

Trial Officials

Amy R Deipolyi, M.D., Ph.D.

Principal Investigator

CAMC Department of Interventional Radiology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported